American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6327)
  2. Solid Tumor Oncology Division (5470)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1750)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1466)
  7. GSK Faculty (1371)
  8. Population Sciences Research Program (1355)
  9. Gastrointestinal Oncology Service (1341)
  10. Hematologic Malignancies, Division of (1267)
Search Within
Formats
  1. Meeting Abstract (6252)
  2. Journal Article (2553)
  3. Editorial (71)
  4. Review (65)
  5. Guidelines (53)
  6. Correspondence (47)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6327)
  2. Solid Tumor Oncology Division (5470)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1750)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1466)

More Groups

People
  1. Robert Motzer (447)
  2. Howard Scher (334)
  3. Eileen O'Reilly (302)
  4. Leonard Saltz (283)
  5. Dean Bajorin (278)
  6. Mark Kris (252)

More People

Years
  1. 2025 (156)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. JCO Precision Oncology (165)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. ASCO Connection (3)

More Publications

Results (9048)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)
    Meeting Abstract

    Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract
    Meeting Abstract

    Chawla, N. S.; Mercier, B. D.; Govindarajan, A.; Li, X.; Castro, D. V.; Ebrahimi, H.; Barragan-Carrillo, R.; Zang, P. D.; Levee, A. A.; Dizman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
    Meeting Abstract

    Iyer, G.; Palma, N. A.; Navarro, W. H.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Mercier, B. D.; Tripathi, N.; Govindarajan, A.; Gebrael, G.; Narang, A.; Li, X.; Castro, D. V.; Chehrazi-Raffle, A.; Dizman, N.; Ebrahimi, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save